InterMune Acquisition Could Ignite These Biotech ETFs
August 25, 2014 at 09:00 AM EDT
Monday could prove to be another day of biotechnology merger mania for the exchange traded funds holding the sector’s stocks after Swiss pharmaceuticals giant Roche announced Sunday it will acquire InterMune (NasdaqGS: ITMN) for $8.3 billion in cash. Roche will pay $74 per share for InterMune,...